Skip Navigation

Mark Yarchoan, M.D.

Mark Yarchoan, M.D.

Headshot of Mark Yarchoan
  • Assistant Professor of Oncology

Expertise

Cholangiocarcinoma, Gastrointestinal Cancers, Hepatobiliary Malignancies, Hepatocellular Cancer, Liver Cancer ...read more

Request an Appointment

Insurance Information

Main Phone

Outside of Maryland & Washington D.C.

Request Appointment

International Patients

Request Appointment

Locations

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Appointment Phone: 410-955-8964
401 N. Broadway
Baltimore, MD 21231 map
Phone: 410-955-8974

The Bunting Blaustein Cancer Research Building

Appointment Phone: 410-955-8964
1650 Orleans Street
Baltimore, MD 21287 map

Background

Dr. Mark Yarchoan is an oncologist in Baltimore, caring for patients with gastrointestinal cancers. His clinical focus is on cancers of the liver, including hepatocellular carcinoma and biliary tract cancer (cholangiocarcinoma).

Dr. Yarchoan received his undergraduate degree (cum laude) in neuroscience from Amherst College and earned his M.D. from the Perelman School of Medicine at the University of Pennsylvania. He completed his residency in internal medicine at the Hospital of the University of Pennsylvania and performed a fellowship in medical oncology at Johns Hopkins University School of Medicine. Dr. Yarchoan joined the Johns Hopkins faculty in 2018.

He directs a National Cancer Institute funded laboratory focused on the discovery of novel cancer immunotherapies for hepatobiliary cancers.

Dr. Yarchoan co-leads the Liver Cancer Multidisciplinary Clinic. He has been recognized with an ASCO Young Investigator Award, and the Director’s Teaching Award in Clinical Science, the Cholangiocarcinoma Foundation’s Mark R. Clements Award, and a Conquer Cancer Foundation/ASCO Career Development Award.

...read more

Education

Degrees

  • MD; University of Pennsylvania School of Medicine (2012)

Residencies

  • Internal Medicine; Hospital of the University of Pennsylvania (2015)

Fellowships

  • Medical Oncology; Johns Hopkins University School of Medicine (2018)

Research & Publications

Clinical Trial Keywords

Hepatocellular Carcinoma (HCC); Biliary tract cancer (BTC); Cholangiocarcinoma; Liver Cancer; Immunotherapy; Fibrolamellar hepatocellular carcinoma (FLC)

Clinical Trials

GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer Pancreatic Cancer


DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma Fibrolamellar Hepatocellular Carcinoma (FLC)


A multicenter Phase 2 of atezolizumab with or without cobimetinib in patients with advanced biliary tract cancer, conducted through the NCI Experimental Therapeutics Clinical Trials Network (ETCTN) Study. Role: Co-PI


A single center neoadjuvant study of cabozantinib plus nivolumab in patients with potentially resectable hepatocellular carcinoma (HCC). Role: PI


A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer. Role: Co-PI


A study of perioperative nivolumab with or without relatlimab in patients with resectable hepatocellular carcinoma (HCC). Role: PI

Selected Publications

View all on PubMed

Yarchoan M, Cope L, Anders RA, Noonan A, Goff LW, Goyal L, Lacy J, Li D, Patel A, He AR, Abou-Alfa G, Spencer K, Kim E, Xavier S, Ruggieri A, Davis SL, McRee A, Kunk P, Zhu Q, Wang-Gillam A, Poklepovic A, Chen H, Sharon E, Lesinski GB, Azad N. Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers. J Clin Invest. 2021 Dec 15;131(24):e152670. doi: 10.1172/JCI152670

Yarchoan M, Ho WJ, Mohan A, Shah Y, Vithayathil T, Leatherman J, Dennison L, Zaidi N, Ganguly S, Woolman S, Cruz K, Armstrong TD, Jaffee EM. Effects of B cell–activating factor on tumor immunity. JCI Insight. JCI Insight; 2020 May 21;5(10)

Yarchoan M, Huang C, Zhu Q, Ferguson AK, Durham JN, Anders RA, Thompson ED, Rozich NS, Thomas DL, Nauroth JM, Rodriguez C, Osipov A, De Jesus‐Acosta A, Le DT, Murphy AG, Laheru D, Donehower RC, Jaffee EM, Zheng L, Azad NS (2020) A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer. Cancer Med 9: 1485–1494, doi:10.1002/cam4.2763

Ho WJ, Zhu Q, Durham J, Popovic A, Xavier S, Leatherman J, Mohan A, Mo G, Zhang S, Gross N, Charmsaz S, Lin D, Quong D, Wilt B, Kamel IR, Weiss M, Philosophe B, Burkhart R, Burns WR, Shubert C, Ejaz A, He J, Deshpande A, Danilova L, Stein-O’Brien G, Sugar EA, Laheru DA, Anders RA, Fertig EJ, Jaffee EM, Yarchoan M. Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity. Nat Cancer. 2021 Jul 29;1–13

Yarchoan M, Hopkins A, Jaffee EM (2017) Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med 377: 2500–2501. PMCID: PMC6549688

Activities & Honors

Honors

  • Director’s Teaching Award in Clinical Science, 2019
  • Incyte Young Investigator Award for Translational Science, 2019
  • ASCO Young Investigator Award, Conquer Cancer Foundation, 2017
  • Inaugural Linda Rubin Fellowship Recipient, Johns Hopkins, 2017
  • ASCO Career Development Award, Conquer Cancer Foundation/ASCO, 2021
  • Cholangiocarcinoma Foundation Mark R. Clements Award, Cholangiocarcinoma Foundation, 2021
Is this you? Edit Profile
back to top button